1.
|
Armitage JO: Treatment of non-Hodgkin’s
lymphoma. N Engl J Med. 328:1023–1030. 1993.
|
2.
|
Sawas A, Diefenbach C and O’Connor OA: New
therapeutic targets and drugs in non-Hodgkin’s lymphoma. Curr Opin
Hematol. 18:280–287. 2011.
|
3.
|
Ferrario A, Pulsoni A, Olivero B, et al:
Fludarabine, cyclophosphamide, and rituximab in patients with
advanced, untreated, indolent B-cell nonfollicular lymphomas: phase
2 study of the Italian Lymphoma Foundation. Cancer. 118:3954–3961.
2012. View Article : Google Scholar : PubMed/NCBI
|
4.
|
Montoto S and Fitzgibbon J: Transformation
of indolent B-cell lymphomas. J Clin Oncol. 29:1827–1834. 2011.
View Article : Google Scholar
|
5.
|
Molina A: A decade of rituximab: improving
survival outcomes in non-Hodgkin’s lymphoma. Annu Rev Med.
59:237–250. 2008.PubMed/NCBI
|
6.
|
Coyle AJ and Gutierrez-Ramos JC: The
expanding B7 superfamily: increasing complexity in costimulatory
signals regulating T cell function. Nat Immunol. 2:203–209. 2001.
View Article : Google Scholar : PubMed/NCBI
|
7.
|
Lanier LL, O’Fallon S, Somoza C, et al:
CD80 (B7) and CD86 (B70) provide similar costimulatory signals for
T cell proliferation, cytokine production, and generation of CTL. J
Immunol. 154:97–105. 1995.PubMed/NCBI
|
8.
|
Pardoll DM: The blockade of immune
checkpoints in cancer immunotherapy. Nat Rev Cancer. 12:252–264.
2012. View
Article : Google Scholar : PubMed/NCBI
|
9.
|
Dorfman DM, Schultze JL, Shahsafaei A, et
al: In vivo expression of B7-1 and B7-2 by follicular lymphoma
cells can prevent induction of T-cell anergy but is insufficient to
induce significant T-cell proliferation. Blood. 90:4297–4306.
1997.PubMed/NCBI
|
10.
|
Munro JM, Freedman AS, Aster JC, et al: In
vivo expression of the B7 costimulatory molecule by subsets of
antigen-presenting cells and the malignant cells of Hodgkin’s
disease. Blood. 83:793–798. 1994.PubMed/NCBI
|
11.
|
Vyth-Dreese FA, Dellemijn TA, Majoor D and
de Jong D: Localization in situ of the co-stimulatory molecules
B7.1, B7.2, CD40 and their ligands in normal human lymphoid tissue.
Eur J Immunol. 25:3023–3029. 1995. View Article : Google Scholar : PubMed/NCBI
|
12.
|
Delabie J, Ceuppens JL, Vandenberghe P, de
Boer M, Coorevits L and De Wolf-Peeters C: The B7/BB1 antigen is
expressed by Reed-Sternberg cells of Hodgkin’s disease and
contributes to the stimulating capacity of Hodgkin’s
disease-derived cell lines. Blood. 82:2845–2852. 1993.PubMed/NCBI
|
13.
|
Suvas S, Singh V, Sahdev S, Vohra H and
Agrewala JN: Distinct role of CD80 and CD86 in the regulation of
the activation of B cell and B cell lymphoma. J Biol Chem.
277:7766–7775. 2002. View Article : Google Scholar : PubMed/NCBI
|
14.
|
Czuczman MS, Thall A, Witzig TE, et al:
Phase I/II study of galiximab, an anti-CD80 antibody, for relapsed
or refractory follicular lymphoma. J Clin Oncol. 23:4390–4398.
2005. View Article : Google Scholar : PubMed/NCBI
|
15.
|
Leonard JP, Friedberg JW, Younes A, et al:
A phase I/II study of galiximab (an anti-CD80 monoclonal antibody)
in combination with rituximab for relapsed or refractory,
follicular lymphoma. Ann Oncol. 18:1216–1223. 2007. View Article : Google Scholar : PubMed/NCBI
|
16.
|
Czuczman MS, Leonard JP, Jung S, et al:
Phase II trial of galiximab (anti-CD80 monoclonal antibody) plus
rituximab (CALGB 50402): Follicular Lymphoma International
Prognostic Index (FLIPI) score is predictive of upfront
immunotherapy responsiveness. Ann Oncol. 23:2356–2362. 2012.
View Article : Google Scholar
|
17.
|
Martinez-Paniagua MA, Vega MI,
Huerta-Yepez S, et al: Galiximab signals B-NHL cells and inhibits
the activities of NF-kappaB-induced YY1- and snail-resistant
factors: mechanism of sensitization to apoptosis by
chemoimmuno-therapeutic drugs. Mol Cancer Ther. 11:572–581. 2012.
View Article : Google Scholar
|
18.
|
Younes A, Hariharan K, Allen RS and Leigh
BR: Initial trials of anti-CD80 monoclonal antibody (Galiximab)
therapy for patients with relapsed or refractory follicular
lymphoma. Clin Lymphoma. 3:257–259. 2003. View Article : Google Scholar : PubMed/NCBI
|
19.
|
Vega MI, Huerta-Yepez S, Jazirehi AR,
Garban H and Bonavida B: Rituximab (chimeric anti-CD20) sensitizes
B-NHL cell lines to Fas-induced apoptosis. Oncogene. 24:8114–8127.
2005.PubMed/NCBI
|
20.
|
Jazirehi AR and Bonavida B: Cellular and
molecular signal transduction pathways modulated by rituximab
(rituxan, anti-CD20 mAb) in non-Hodgkin’s lymphoma: implications in
chemosensitization and therapeutic intervention. Oncogene.
24:2121–2143. 2005.PubMed/NCBI
|
21.
|
Vega MI, Baritaki S, Huerta-Yepez S,
Martinez-Paniagua MA and Bonavida B: A potential mechanism of
rituximab-induced inhibition of tumor growth through its
sensitization to tumor necrosis factor-related apoptosis-inducing
ligand-expressing host cytotoxic cells. Leuk Lymphoma. 52:108–121.
2011. View Article : Google Scholar
|